Power Law company profile

Jounce Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2017 Thoroughbred

A clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients

Revenue

$82M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

10 investors on Jounce Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Third Rock Ventures

Series B+ 9 investors entered at this stage

Casdin Capital

Cormorant Asset Management

Nextech Invest

Inbio Ventures

Foresite Capital

Redmile Group

Omega Funds

Wellington Management

Pharmstandard

Global footprint

Where Jounce Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States88.9%

🇲🇦 Morocco11.1%

2 countries shown

Market sentiment

What the market is saying about Jounce Therapeutics

An AI-synthesized read of the highest-engagement posts about Jounce Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Jounce Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles